Skip to main content
Signal8

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Brainstorm Cell Therapeutics Inc. logo

Brainstorm Cell Therapeutics Inc.

OTC:BCLIHealthcare
AH+0.00%$0.8810
Close$0.8810-7.26%
Mkt Cap$12.56M
EV-
Float11.42M
O/S14.26M
VOL83K sh
$ Vol$79K
RVOL3.75×
Inst Own-
SI0.5%
Net Cash/Sh-
Dilution
Brainstorm Cell Therapeutics Inc. logoOTC:BCLIAH$0.8810+0.00%
Short interest (FINRA)
0.5%
Oct 30 (19d)

Float 11.42M · Signal8 dilution snapshot · Nov 16, 2026

60.6K
Oct 30 (19d)prev 34.2K▲ 77.0%
2.01
Oct 30 (19d)prev 1.47▲ 36.7%
Borrow (IBKR)

The cost to borrow BCLI shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
87.9%
Nov 17 (1d)prev 33.0%▲ 54.9 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

5.0K
Aug 19 (91d)prev 100▲ 4862.0%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver2 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202660.6K sh
Oct 15, 202634.2K sh
Sep 30, 202636.5K sh
Sep 15, 202642.4K sh
Aug 31, 202649.1K sh
Latest fails to deliver
DateShares failed
Aug 19, 20265.0K sh
Jun 10, 2026100 sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 17
Latest sessions
DateReported short
Nov 17, 202687.9%
Nov 13, 202633.0%
Nov 12, 202641.0%
Nov 11, 202640.8%
Nov 10, 202624.6%
83-session median 29.9%mean 30.4%range 0.1–83.2%

130 calendar days requested; 84 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for BCLI: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 60,573 BCLI shares were sold short (0.53% of a 11.42M-share float, 2.01 days to cover).